Results 211 to 220 of about 30,536 (239)

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

The Lancet Oncology, 2018
C. Dinardo, K. Pratz, A. Letai, B. Jonas, A. Wei, M. Thirman, M. Arellano, M. Frattini, H. Kantarjian, R. Popovic, B. Chyla, T. Xu, M. Dunbar, S. Agarwal, R. Humerickhouse, M. Mabry, J. Potluri, M. Konopleva, D. Pollyea   +18 more
semanticscholar   +1 more source

Decitabine

Reactions Weekly, 2022
openaire   +2 more sources

Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.

The Lancet Haematology
Guillermo Garcia‐manero, James K. McCloskey, Elizabeth A. Griffiths, K. Yee, A. Zeidan, A. Al-Kali, H. Deeg, Prapti A Patel, M. Sabloff, M. Keating, N. Zhu, N. Gabrail, Salman Fazal, Joseph J. Maly, O. Odenike, Hagop Kantarjian, A. Dezern, Casey L. O'Connell, G. Roboz, L. Busque, R. Buckstein, Harsh V. Amin, J. Randhawa, Brian Leber, A. Shastri, Kim-Hien Dao, A. Oganesian, Y. Hao, H.N. Keer, M. Azab, M. Savona   +30 more
semanticscholar   +1 more source

Decitabine

Reactions Weekly, 2020
openaire   +2 more sources

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

American Journal of Hematology, 2021
Daniel A Pollyea, Anthony G Letai, Brian A Jonas   +2 more
exaly  

DECITABINE

Reactions Weekly, 2015
openaire   +2 more sources

A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia

Supportive Care in Cancer, 2022
Li-xia Zhu, Rong-rong Chen, Lulu Wang, Jianai Sun, De Zhou, Li Li, J. Qian, Yi Zhang, H. Tong, Wenjuan Yu, H. Meng, W. Mai, W. Xie, J. Jin, X. Ye, Hongmei Zhu   +15 more
semanticscholar   +1 more source

Decitabine improves patient outcomes in myelodysplastic syndromes

Cancer, 2006
Hagop M Kantarjian, Jean-Pierre J Issa, Farhad Ravandi   +2 more
exaly  

Decitabine

Drugs of the Future, 1990
W.P. Vrijhof, D. De Vos
openaire   +1 more source

Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment

Cellular and Molecular Immunology, 2018
Xuetao Cao
exaly